CEL-SCI Corporation (NYSE American: CVM), a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.


Business Strategy

CEL-SCI's vision is to change the way cancer is treated. We strive to develop novel immune-based therapies with potential to utilize the body's own immune defense system against the disease with the possibility of minimal toxicity to normal cells and organ systems.

CEL-SCI's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is currently being developed as a potential therapeutic agent directed at enabling the immune system to use the body's own anti-tumor immune response.

Read more...

Mission & Values


  • Be science based and data driven
  • Take a 'no-shortcuts' approach to drug development
  • Reward bold innovation
  • Create and maintain shareholder value
  • Be ethical and conduct ourselves with integrity
  • Be economical in our day-to-day approach to running our business
  • Communicate openly about our progress

History

CEL-SCI’s story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, many times lack of funding, a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer and having to switch and sue the Clinical Research Organization that initially ran the Phase 3 trial, CEL-SCI is finally approaching the end game!

Read more...

“CEL-SCI has a dedicated and passionate team that believes boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival when it comes to cancer immunotherapy.”
.

Geert R. Kersten

Director and Chief
Executive Officer

OUR TEAM

Executive Officers



Geert R. Kersten
Director and Chief Executive Officer

Geert Kersten has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI from the early days of its inception since 1987.

read more

Eyal Talor, Ph.D.
Chief Scientific Officer

Eyal Talor joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing.

read more

Patricia B. Prichep
Senior Vice President of Operations

Patricia B. Prichep has over 30 years experience in business operations and administration. She joined CEL-SCI in 1992 and has been CEL-SCI's Senior Vice President of Operations since March 1994.

read more

Daniel Zimmerman, Ph.D.
Senior Vice President of Cellular Immunology

Daniel H. Zimmerman, Ph.D., is the Senior Vice President of Research, Cellular Immunology for CEL-SCI Corporation and head of the L.E.A.P.S. technology program.

read more


John Cipriano
Senior Vice President of Regulatory Affairs

John Cipriano, is CEL-SCI's Senior Vice President of Regulatory Affairs. Mr. Cipriano brings to CEL-SCI over 30 years of experience in both biotech and pharmaceutical companies.

read more

William "Brooke" Jones
Vice President of Quality Assurance

William "Brooke" Jones has been with CEL-SCI since 1999 and has overall responsibility for Quality Assurance.

read more

Todd Burkhart
Vice President of Manufacturing

Todd S. Burkhart joined CEL-SCI Corporation as Vice President of Manufacturing/Facilities and Commercial Operations in January 2010.

read more

Board of Directors



Geert R. Kersten
Director and Chief Executive Officer

Geert Kersten has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI from the early days of its inception since 1987.

read more

Peter R. Young Ph.D.
Director

Peter R. Young, Ph.D. has been a Director of CEL-SCI since August 2002. Dr. Young has been a senior executive within the pharmaceutical industry in the United States and Canada for most of his career, originally in organizations that are now part of Sanofi S.A.

read more

Bruno Baillavoine
Director

Mr. Baillavoine has been a Director of CEL-SCI since June 2015. Since 2017 Mr. Baillavoine has been the Director, Head of Pericles Group UK the subsidiary of the Paris based leading French consulting firm.

read more

Robert Watson
Director

Mr. Watson has been a director oF CEL-SCI since December 2017. He joined Intermedix, Inc. in July 2017 as President of their Preparedness Technology Division.

read more